Table of Contents Author Guidelines Submit a Manuscript
PPAR Research
Volume 2011, Article ID 867180, 9 pages
http://dx.doi.org/10.1155/2011/867180
Review Article

Thiazolidinediones on PPARγ: The Roles in Bone Remodeling

Department of Pharmacology, UT Southwestern Medical Center, Dallas, TX 75390, USA

Received 27 August 2011; Revised 4 October 2011; Accepted 5 October 2011

Academic Editor: Beata Lecka-Czernik

Copyright © 2011 Wei Wei and Yihong Wan. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. O. Johnell and J. A. Kanis, “An estimate of the worldwide prevalence and disability associated with osteoporotic fractures,” Osteoporosis International, vol. 17, no. 12, pp. 1726–1733, 2006. View at Publisher · View at Google Scholar · View at Scopus
  2. L. J. Melton III, E. J. Atkinson, M. K. O'Connor, W. M. O'Fallon, and B. L. Riggs, “Bone density and fracture risk in men,” Journal of Bone and Mineral Research, vol. 13, no. 12, pp. 1915–1923, 1998. View at Google Scholar · View at Scopus
  3. L. J. Melton III, E. A. Chrischilles, C. Cooper, A. W. Lane, and B. L. Riggs, “Perspective: how many women have osteoporosis?” Journal of Bone and Mineral Research, vol. 7, no. 9, pp. 1005–1010, 1992. View at Google Scholar · View at Scopus
  4. J. A. Kanis, O. Johnell, A. Oden et al., “Long-term risk of osteoporotic fracture in Malmo,” Osteoporosis International, vol. 11, no. 8, pp. 669–674, 2000. View at Publisher · View at Google Scholar · View at Scopus
  5. B. Gullberg, O. Johnell, and J. A. Kanis, “World-wide projections for hip fracture,” Osteoporosis International, vol. 7, no. 5, pp. 407–413, 1997. View at Publisher · View at Google Scholar · View at Scopus
  6. J. A. Kanis, P. Delmas, P. Burckhardt et al., “Guidelines for diagnosis and management of osteoporosis. The European Foundation for Osteoporosis and Bone Disease,” Osteoporosis International, vol. 7, no. 4, pp. 390–406, 1997. View at Google Scholar
  7. T. V. Nguyen, J. R. Center, and J. A. Eisman, “Osteoporosis: underrated, underdiagnosed and undertreated,” Medical Journal of Australia, vol. 180, supplement 5, pp. S18–S22, 2004. View at Google Scholar · View at Scopus
  8. W. J. Boyle, W. S. Simonet, and D. L. Lacey, “Osteoclast differentiation and activation,” Nature, vol. 423, no. 6937, pp. 337–342, 2003. View at Publisher · View at Google Scholar · View at Scopus
  9. J. R. Edwards and G. R. Mundy, “Advances in osteoclast biology: old findings and new insights from mouse models,” Nature Reviews Rheumatology, vol. 7, no. 4, pp. 235–243, 2011. View at Publisher · View at Google Scholar
  10. D. V. Novack and S. L. Teitelbaum, “The osteoclast: friend or foe?” Annual Review of Pathology, vol. 3, pp. 457–484, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. S. L. Teitelbaum and F. P. Ross, “Genetic regulation of osteoclast development and function,” Nature Reviews Genetics, vol. 4, no. 8, pp. 638–649, 2003. View at Publisher · View at Google Scholar · View at Scopus
  12. Y. Wan, “PPARγ in bone homeostasis,” Trends in Endocrinology and Metabolism, vol. 21, no. 12, pp. 722–728, 2010. View at Google Scholar
  13. G. Karsenty, “Transcriptional control of skeletogenesis,” Annual Review of Genomics and Human Genetics, vol. 9, pp. 183–196, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. A. G. Robling, A. B. Castillo, and C. H. Turner, “Biomechanical and molecular regulation of bone remodeling,” Annual Review of Biomedical Engineering, vol. 8, pp. 455–498, 2006. View at Publisher · View at Google Scholar · View at Scopus
  15. G. Karsenty, H. M. Kronenberg, and C. Settembre, “Genetic control of bone formation,” Annual Review of Cell and Developmental Biology, vol. 25, pp. 629–648, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. C. R. Jacobs, S. Temiyasathit, and A. B. Castillo, “Osteocyte mechanobiology and pericellular mechanics,” Annual Review of Biomedical Engineering, vol. 12, pp. 369–400, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. L. F. Bonewald, “The amazing osteocyte,” Journal of Bone and Mineral Research, vol. 26, no. 2, pp. 229–238, 2011. View at Google Scholar
  18. J. J. Nolan, B. Ludvik, P. Beerdsen, M. Joyce, and J. Olefsky, “Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone,” New England Journal of Medicine, vol. 331, no. 18, pp. 1188–1193, 1994. View at Publisher · View at Google Scholar · View at Scopus
  19. S. L. Suter, J. J. Nolan, P. Wallace, B. Gumbiner, and J. M. Olefsky, “Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects,” Diabetes Care, vol. 15, no. 2, pp. 193–203, 1992. View at Google Scholar · View at Scopus
  20. S. E. Kahn, S. M. Haffner, M. A. Heise et al., “Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy,” New England Journal of Medicine, vol. 355, no. 23, pp. 2427–2443, 2006. View at Publisher · View at Google Scholar · View at Scopus
  21. Takeda, “Observation of an increased incidence of fractures in female patients who received long-term treatment with ACTOS® (pioglitazone HCl) tablets for type 2 diabetes mellitus. (Letter to Health Care Providers),” http://www.fda.gov/downloads/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/UCM153896.pdf, March 2007.
  22. B. Zinman, S. M. Haffner, W. H. Herman et al., “Effect of rosiglitazone, metformin, and glyburide on bone biomarkers in patients with type 2 diabetes,” Journal of Clinical Endocrinology and Metabolism, vol. 95, no. 1, pp. 134–142, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. O. P. Lazarenko, S. O. Rzonca, W. R. Hogue, F. L. Swain, L. J. Suva, and B. Lecka-Czernik, “Rosiglitazone induces decreases in bone mass and strength that are reminiscent of aged bone,” Endocrinology, vol. 148, no. 6, pp. 2669–2680, 2007. View at Publisher · View at Google Scholar · View at Scopus
  24. A. Grey, “Thiazolidinedione-induced skeletal fragility—mechanisms and implications,” Diabetes, Obesity and Metabolism, vol. 11, no. 4, pp. 275–284, 2009. View at Publisher · View at Google Scholar · View at Scopus
  25. E. S. Strotmeyer and J. A. Cauley, “Diabetes mellitus, bone mineral density, and fracture risk,” Current Opinion in Endocrinology, Diabetes and Obesity, vol. 14, no. 6, pp. 429–435, 2007. View at Publisher · View at Google Scholar · View at Scopus
  26. L. R. McCabe, “Understanding the pathology and mechanisms of type I diabetic bone loss,” Journal of Cellular Biochemistry, vol. 102, no. 6, pp. 1343–1357, 2007. View at Publisher · View at Google Scholar · View at Scopus
  27. F. J. de Paula, M. C. Horowitz, and C. J. Rosen, “Novel insights into the relationship between diabetes and osteoporosis,” Diabetes/Metabolism Research and Reviews, vol. 26, no. 8, pp. 622–630, 2010. View at Publisher · View at Google Scholar · View at Scopus
  28. Y. Hamada, H. Fujii, and M. Fukagawa, “Role of oxidative stress in diabetic bone disorder,” Bone, vol. 45, supplement 1, pp. S35–S38, 2009. View at Publisher · View at Google Scholar · View at Scopus
  29. P. Tontonoz and B. M. Spiegelman, “Fat and beyond: the diverse biology of PPARγ,” Annual Review of Biochemistry, vol. 77, pp. 289–312, 2008. View at Publisher · View at Google Scholar · View at Scopus
  30. T. Akune, S. Ohba, S. Kamekura et al., “PPARγ insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors,” Journal of Clinical Investigation, vol. 113, no. 6, pp. 846–855, 2004. View at Publisher · View at Google Scholar · View at Scopus
  31. A. A. Ali, R. S. Weinstein, S. A. Stewart, A. M. Parfitt, S. C. Manolagas, and R. L. Jilka, “Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation,” Endocrinology, vol. 146, no. 3, pp. 1226–1235, 2005. View at Publisher · View at Google Scholar · View at Scopus
  32. B. Lecka-Czernik, I. Gubrij, E. J. Moerman et al., “Inhibition of Osf2/Cbfa1 expression and terminal osteoblast differentiation by PPARγ2,” Journal of Cellular Biochemistry, vol. 74, no. 3, pp. 357–371, 1999. View at Publisher · View at Google Scholar · View at Scopus
  33. S. O. Rzonca, L. J. Suva, D. Gaddy, D. C. Montague, and B. Lecka-Czernik, “Bone is a target for the antidiabetic compound rosiglitazone,” Endocrinology, vol. 145, no. 1, pp. 401–406, 2004. View at Publisher · View at Google Scholar · View at Scopus
  34. G. Mabilleau, A. Mieczkowska, and M. E. Edmonds, “Thiazolidinediones induce osteocyte apoptosis and increase sclerostin expression,” Diabetic Medicine, vol. 27, no. 8, pp. 925–932, 2010. View at Publisher · View at Google Scholar · View at Scopus
  35. M. A. Sorocéanu, D. Miao, X. Y. Bai, H. Su, D. Goltzman, and A. C. Karaplis, “Rosiglitazone impacts negatively on bone by promoting osteoblast/osteocyte apoptosis,” Journal of Endocrinology, vol. 183, no. 1, pp. 203–216, 2004. View at Publisher · View at Google Scholar · View at Scopus
  36. Y. Wan, L. W. Chong, and R. M. Evans, “PPAR-γ regulates osteoclastogenesis in mice,” Nature Medicine, vol. 13, no. 12, pp. 1496–1503, 2007. View at Publisher · View at Google Scholar · View at Scopus
  37. W. Wei, X. Wang, M. Yang, L. C. Smith, P. C. Dechow, and Y. Wan, “PGC1β mediates PPARγ activation of osteoclastogenesis and rosiglitazone-induced bone loss,” Cell Metabolism, vol. 11, no. 6, pp. 503–516, 2010. View at Publisher · View at Google Scholar · View at Scopus
  38. W. Wei, D. Zeve, J. M. Suh et al., “Biphasic and dosage-dependent regulation of osteoclastogenesis by ß-catenin,” Molecular and Cellular Biology. In press. View at Publisher · View at Google Scholar
  39. J. Pfeilschifter, C. Chenu, A. Bird, G. R. Mundy, and G. D. Roodman, “Interleukin-1 and tumor necrosis factor stimulate the formation of human osteoclastlike cells in vitro,” Journal of Bone and Mineral Research, vol. 4, no. 1, pp. 113–118, 1989. View at Google Scholar · View at Scopus
  40. K. Kobayashi, N. Takahashi, E. Jimi et al., “Tumor necrosis factor α stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction,” Journal of Experimental Medicine, vol. 191, no. 2, pp. 275–286, 2000. View at Publisher · View at Google Scholar · View at Scopus
  41. J. R. Edwards, S. G. Sun, R. Locklin et al., “LIGHT (TNFSF14), a novel mediator of bone resorption, is elevated in rheumatoid arthritis,” Arthritis and Rheumatism, vol. 54, no. 5, pp. 1451–1462, 2006. View at Publisher · View at Google Scholar · View at Scopus
  42. Y. Ishimi, C. Miyaura, C. H. Jin et al., “IL-6 is produced by osteoblasts and induces bone resorption,” Journal of Immunology, vol. 145, no. 10, pp. 3297–3303, 1990. View at Google Scholar · View at Scopus
  43. T. Tamura, N. Udagawa, N. Takahashi et al., “Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6,” Proceedings of the National Academy of Sciences of the United States of America, vol. 90, no. 24, pp. 11924–11928, 1993. View at Publisher · View at Google Scholar · View at Scopus
  44. Y. Fujikawa, A. Sabokbar, S. D. Neale, I. Itonaga, T. Torisu, and N. A. Athanasou, “The effect of macrophage-colony stimulating factor and other humoral factors (interleukin-1, -3, -6, and -11, tumor necrosis factor-α, and granulocyte macrophage-colony stimulating factor) on human osteoclast formation from circulating cells,” Bone, vol. 28, no. 3, pp. 261–267, 2001. View at Publisher · View at Google Scholar · View at Scopus
  45. I. Itonaga, A. Sabokbar, S. G. Sun et al., “Transforming growth factor-β induces osteoclast formation in the absence of RANKL,” Bone, vol. 34, no. 1, pp. 57–64, 2004. View at Publisher · View at Google Scholar · View at Scopus
  46. F. Hemingway, R. Taylor, H. J. Knowles, and N. A. Athanasou, “RANKL-independent human osteoclast formation with APRIL, BAFF, NGF, IGF I and IGF II,” Bone, vol. 48, no. 4, pp. 938–944, 2011. View at Publisher · View at Google Scholar
  47. P. D. Home, S. J. Pocock, H. Beck-Nielsen et al., “Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial,” The Lancet, vol. 373, no. 9681, pp. 2125–2135, 2009. View at Publisher · View at Google Scholar · View at Scopus
  48. S. E. Kahn, B. Zinman, J. M. Lachin et al., “Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT),” Diabetes Care, vol. 31, no. 5, pp. 845–851, 2008. View at Google Scholar
  49. M. Li, L. C. Pan, H. A. Simmons et al., “Surface-specific effects of a PPARγ agonist, darglitazone, on bone in mice,” Bone, vol. 39, no. 4, pp. 796–806, 2006. View at Publisher · View at Google Scholar · View at Scopus
  50. V. Sottile, K. Seuwen, and M. Kneissel, “Enhanced marrow adipogenesis and bone resorption in estrogen-deprived rats treated with the PPARγ agonist BRL49653 (rosiglitazone),” Calcified Tissue International, vol. 75, no. 4, pp. 329–337, 2004. View at Publisher · View at Google Scholar · View at Scopus
  51. T. D. Rachner, S. Khosla, and L. C. Hofbauer, “Osteoporosis: now and the future,” The Lancet, vol. 377, no. 9773, pp. 1276–1287, 2011. View at Publisher · View at Google Scholar
  52. K. Takagi and A. Kudo, “Bone marrow stromal cell lines having high potential for osteoclast-supporting activity express PPARγ1 and show high potential for differentiation into adipocytes,” Journal of Bone and Mineral Metabolism, vol. 26, no. 1, pp. 13–23, 2008. View at Publisher · View at Google Scholar · View at Scopus
  53. S. W. Cho, J. Y. Yang, S. J. Her et al., “Osteoblast-targeted overexpression of PPAR? inhibited bone mass gain in male mice and accelerated ovariectomy-induced bone loss in female mice,” Journal of Bone and Mineral Research, vol. 26, no. 8, pp. 1939–1952, 2011. View at Google Scholar
  54. J. S. Park, M. H. Cho, J. S. Nam et al., “Effect of pioglitazone on serum concentrations of osteoprotegerin in patients with type 2 diabetes mellitus,” European Journal of Endocrinology, vol. 164, no. 1, pp. 69–74, 2011. View at Publisher · View at Google Scholar
  55. A. Sultan, A. Avignon, F. Galtier et al., “Osteoprotegerin, thiazolidinediones treatment, and silent myocardial ischemia in type 2 diabetic patients,” Diabetes Care, vol. 31, no. 3, pp. 593–595, 2008. View at Publisher · View at Google Scholar · View at Scopus
  56. U. Krause, S. Harris, A. Green et al., “Pharmaceutical modulation of canonical Wnt signaling in multipotent stromal cells for improved osteoinductive therapy,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 9, pp. 4147–4152, 2010. View at Publisher · View at Google Scholar · View at Scopus
  57. S. A. Krum, “Direct transcriptional targets of sex steroid hormones in bone,” Journal of Cellular Biochemistry, vol. 112, no. 2, pp. 401–408, 2011. View at Publisher · View at Google Scholar
  58. W. Wei, D. Zeve, X. Wang et al., “Osteoclast progenitors reside in PPAR ?-expressing bone marrow cell population,” Molecular and Cellular Biology. In press.
  59. S. A. Krum, G. A. Miranda-Carboni, P. V. Hauschka et al., “Estrogen protects bone by inducing Fas ligand in osteoblasts to regulate osteoclast survival,” EMBO Journal, vol. 27, no. 3, pp. 535–545, 2008. View at Publisher · View at Google Scholar · View at Scopus
  60. T. Nakamura, Y. Imai, T. Matsumoto et al., “Estrogen prevents bone loss via estrogen receptor α and induction of fas ligand in osteoclasts,” Cell, vol. 130, no. 5, pp. 811–823, 2007. View at Publisher · View at Google Scholar · View at Scopus
  61. D. Bilik, L. N. McEwen, M. B. Brown et al., “Thiazolidinediones and fractures: evidence from translating research into action for diabetes,” Journal of Clinical Endocrinology and Metabolism, vol. 95, no. 10, pp. 4560–4565, 2010. View at Publisher · View at Google Scholar · View at Scopus
  62. A. Grey, M. Bolland, G. Gamble et al., “The peroxisome proliferator-activated receptor-γ agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial,” Journal of Clinical Endocrinology and Metabolism, vol. 92, no. 4, pp. 1305–1310, 2007. View at Publisher · View at Google Scholar · View at Scopus
  63. S. Benvenuti, I. Cellai, P. Luciani et al., “Androgens and estrogens prevent rosiglitazone-induced adipogenesis in human mesenchymal stem cells,” Journal of Endocrinology Investment. In press.
  64. D. Seto-Young, D. Avtanski, G. Parikh et al., “Rosiglitazone and pioglitazone inhibit estrogen synthesis in human granulosa cells by interfering with androgen binding to aromatase,” Hormone and Metabolic Research, vol. 43, no. 4, pp. 250–256, 2011. View at Publisher · View at Google Scholar
  65. J. Lecomte, S. Flament, S. Salamone et al., “Disruption of ERa signalling pathway by PPAR? agonists: evidences of PPAR?-independent events in two hormone-dependent breast cancer cell lines,” Breast Cancer Research and Treatment, vol. 112, no. 3, pp. 437–451, 2008. View at Google Scholar
  66. D. Bonofiglio, S. Gabriele, S. Aquila et al., “Peroxisome proliferator-activated receptor γ activates fas ligand gene promoter inducing apoptosis in human breast cancer cells,” Breast Cancer Research and Treatment, vol. 113, no. 3, pp. 423–434, 2009. View at Publisher · View at Google Scholar · View at Scopus
  67. J. M. Vanacker, E. Bonnelye, S. Chopin-Delannoy et al., “Transcriptional activities of the orphan nuclear receptor ERR a (estrogen receptor-related receptor-a),” Molecular Endocrinology, vol. 13, no. 5, pp. 764–773, 1999. View at Google Scholar · View at Scopus
  68. J. M. Vanacker, K. Pettersson, J. A. Gustafsson, and V. Laudet, “Transcriptional targets shared by estrogen receptor-related receptors (ERRs) and estrogen receptor (ER) α, but not by ERβ,” EMBO Journal, vol. 18, no. 15, pp. 4270–4279, 1999. View at Publisher · View at Google Scholar · View at Scopus
  69. R. A. Stein and D. P. McDonnell, “Estrogen-related receptor α as a therapeutic target in cancer,” Endocrine-Related Cancer, vol. 13, supplement 1, pp. S25–S32, 2006. View at Google Scholar
  70. M. Gallet and J. M. Vanacker, “ERR receptors as potential targets in osteoporosis,” Trends in Endocrinology and Metabolism, vol. 21, no. 10, pp. 637–641, 2010. View at Publisher · View at Google Scholar · View at Scopus
  71. K. A. Ishii, T. Fumoto, K. Iwai et al., “Coordination of PGC-1β and iron uptake in mitochondrial biogenesis and osteoclast activation,” Nature Medicine, vol. 15, no. 3, pp. 259–266, 2009. View at Publisher · View at Google Scholar · View at Scopus
  72. K. K. Ryan, B. Li, B. E. Grayson et al., “A role for central nervous system PPAR-? in the regulation of energy balance,” Nature Medicine, vol. 17, no. 5, pp. 623–626, 2011. View at Google Scholar
  73. K. M. Nicks, T. W. Fowler, and D. Gaddy, “Reproductive hormones and bone,” Current Osteoporosis Reports, vol. 8, no. 2, pp. 60–67, 2010. View at Publisher · View at Google Scholar · View at Scopus
  74. V. Seifert-Klauss and J. C. Prior, “Progesterone and bone: actions promoting bone health in women,” Journal of Osteoporosis, vol. 2010, Article ID 845180, 2010. View at Google Scholar
  75. D. Schramek, A. Leibbrandt, V. Sigl et al., “Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer,” Nature, vol. 468, no. 7320, pp. 98–102, 2010. View at Publisher · View at Google Scholar · View at Scopus
  76. P. Wang, N. Dharmaraj, M. J. Brayman, and D. D. Carson, “Peroxisome proliferator-activated receptor γ activation inhibits progesterone-stimulated human MUC1 expression,” Molecular Endocrinology, vol. 24, no. 7, pp. 1368–1379, 2010. View at Publisher · View at Google Scholar · View at Scopus
  77. N. Ling, S. Y. Ying, and N. Ueno, “Pituitary FSH is released by a heterodimer of the β-subunits from the two forms of inhibin,” Nature, vol. 321, no. 6072, pp. 779–782, 1986. View at Google Scholar · View at Scopus
  78. K. M. Nicks, D. S. Perrien, N. S. Akel, L. J. Suva, and D. Gaddy, “Regulation of osteoblastogenesis and osteoclastogenesis by the other reproductive hormones, Activin and Inhibin,” Molecular and Cellular Endocrinology, vol. 310, no. 1-2, pp. 11–20, 2009. View at Publisher · View at Google Scholar · View at Scopus
  79. S. Hirai, M. Yamanaka, H. Kawachi, T. Matsui, and H. Yano, “Activin A inhibits differentiation of 3T3-L1 preadipocyte,” Molecular and Cellular Endocrinology, vol. 232, no. 1-2, pp. 21–26, 2005. View at Publisher · View at Google Scholar · View at Scopus
  80. B. M. Necela, W. Su, and E. A. Thompson, “Peroxisome proliferator-activated receptor γ down-regulates follistatin in intestinal epithelial cells through SP1,” Journal of Biological Chemistry, vol. 283, no. 44, pp. 29784–29794, 2008. View at Publisher · View at Google Scholar · View at Scopus
  81. P. R. Ebeling, L. M. Atley, J. R. Guthrie et al., “Bone turnover markers and bone density across the menopausal transition,” Journal of Clinical Endocrinology and Metabolism, vol. 81, no. 9, pp. 3366–3371, 1996. View at Publisher · View at Google Scholar · View at Scopus
  82. M. R. Sowers, J. S. Finkelstein, B. Ettinger et al., “The association of endogenous hormone concentrations and bone mineral density measures in pre- and perimenopausal women of four ethnic groups: SWAN,” Osteoporosis International, vol. 14, no. 1, pp. 44–52, 2003. View at Publisher · View at Google Scholar · View at Scopus
  83. M. R. Sowers, G. A. Greendale, I. Bondarenko et al., “Endogenous hormones and bone turnover markers in pre- and perimenopausal women: SWAN,” Osteoporosis International, vol. 14, no. 3, pp. 191–197, 2003. View at Publisher · View at Google Scholar · View at Scopus
  84. L. Sun, Y. Peng, A. C. Sharrow et al., “FSH directly regulates bone mass,” Cell, vol. 125, no. 2, pp. 247–260, 2006. View at Publisher · View at Google Scholar · View at Scopus
  85. M. T. Drake, L. K. McCready, K. A. Hoey, E. J. Atkinson, and S. Khosla, “Effects of suppression of follicle-stimulating hormone secretion on bone resorption markers in postmenopausal women,” Journal of Clinical Endocrinology and Metabolism, vol. 95, no. 11, pp. 5063–5068, 2010. View at Publisher · View at Google Scholar · View at Scopus
  86. C. M. Allan, R. Kalak, C. R. Dunstan et al., “Follicle-stimulating hormone increases bone mass in female mice,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 52, pp. 22629–22634, 2010. View at Publisher · View at Google Scholar
  87. F. Bogazzi, D. Russo, M. T. Locci et al., “Peroxisome proliferator-activated receptor (PPAR)γ is highly expressed in normal human pituitary gland,” Journal of Endocrinological Investigation, vol. 28, no. 10, pp. 899–904, 2005. View at Google Scholar · View at Scopus
  88. S. Sharma, P. M. Sharma, D. S. Mistry et al., “PPARG regulates gonadotropin-releasing hormone signaling in LβT2 cells in vitro and pituitary gonadotroph function in vivo in mice,” Biology of Reproduction, vol. 84, no. 3, pp. 466–475, 2011. View at Publisher · View at Google Scholar
  89. A. P. Heaney, M. Fernando, and S. Melmed, “PPAR-γ receptor ligands: novel therapy for pituitary adenomas,” Journal of Clinical Investigation, vol. 111, no. 9, pp. 1381–1388, 2003. View at Publisher · View at Google Scholar · View at Scopus
  90. C. Elabd, A. Basillais, H. Beaupied et al., “Oxytocin controls differentiation of human mesenchymal stem cells and reverses osteoporosis,” Stem Cells, vol. 26, no. 9, pp. 2399–2407, 2008. View at Publisher · View at Google Scholar · View at Scopus
  91. S. Colucci, G. Colaianni, G. Mori, M. Grano, and A. Zallone, “Human osteoclasts express oxytocin receptor,” Biochemical and Biophysical Research Communications, vol. 297, no. 3, pp. 442–445, 2002. View at Publisher · View at Google Scholar · View at Scopus
  92. R. Tamma, G. Colaianni, L. L. Zhu et al., “Oxytocin is an anabolic bone hormone,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 17, pp. 7149–7154, 2009. View at Publisher · View at Google Scholar · View at Scopus
  93. M. Eckertova, M. Ondrejcakova, K. Krskova, S. Zorad, and D. Jezova, “Subchronic treatment of rats with oxytocin results in improved adipocyte differentiation and increased gene expression of factors involved in adipogenesis,” British Journal of Pharmacology, vol. 162, no. 2, pp. 452–463, 2011. View at Publisher · View at Google Scholar · View at Scopus
  94. D. Seriwatanachai, K. Thongchote, N. Charoenphandhu et al., “Prolactin directly enhances bone turnover by raising osteoblast-expressed receptor activator of nuclear factor κB ligand/osteoprotegerin ratio,” Bone, vol. 42, no. 3, pp. 535–546, 2008. View at Publisher · View at Google Scholar · View at Scopus
  95. R. Nanbu-Wakao, Y. Fujitani, Y. Masuho, M. A. Muramatu, and H. Wakao, “Prolactin enhances CCAAT enhancer-binding protein-β (C/EBPβ) and peroxisome proliferator-activated receptor γ (PPARγ) messenger RNA expression and stimulates adipogenic conversion of NIH-3T3 cells,” Molecular Endocrinology, vol. 14, no. 2, pp. 307–316, 2000. View at Publisher · View at Google Scholar · View at Scopus
  96. A. Gruszka, J. Kunert-Radek, and M. Pawlikowski, “Rosiglitazone, PPAR-γ receptor ligand, decreases the viability of rat prolactin-secreting pituitary tumor cells in vitro,” Neuroendocrinology Letters, vol. 26, no. 1, pp. 51–54, 2005. View at Google Scholar · View at Scopus
  97. B. Lecka-Czernik, “Bone loss in diabetes: use of antidiabetic thiazolidinediones and secondary osteoporosis,” Current Osteoporosis Reports, vol. 8, no. 4, pp. 178–184, 2010. View at Publisher · View at Google Scholar · View at Scopus
  98. O. P. Lazarenko, S. O. Rzonca, L. J. Suva, and B. Lecka-Czernik, “Netoglitazone is a PPAR-γ ligand with selective effects on bone and fat,” Bone, vol. 38, no. 1, pp. 74–84, 2006. View at Publisher · View at Google Scholar · View at Scopus
  99. J. H. Choi, A. S. Banks, J. L. Estall et al., “Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARγ 3 by Cdk5,” Nature, vol. 466, no. 7305, pp. 451–456, 2010. View at Publisher · View at Google Scholar · View at Scopus
  100. G. Derosa and P. Maffioli, “Thiazolidinediones plus metformin association on body weight in patients with type 2 diabetes,” Diabetes Research and Clinical Practice, vol. 91, no. 3, pp. 265–270, 2011. View at Publisher · View at Google Scholar